Glenmark Pharmaceuticals Signed Dual Agreement For Sustainable Future

In a significant move towards achieving carbon neutrality by 2030, Glenmark Pharmaceuticals Limited (GPL) announced a strategic investment in renewable energy. Through an exchange filing, GPL detailed its agreements with O2 Renewable Energy XXIV Private Limited (O2 Renewables) and O2 Energy SG PTE Limited.

Dual Agreements for a Sustainable Future

The collaboration involves two key agreements:

• Securities Subscription and Shareholders’ Agreement: This agreement allows GPL to acquire a 26% stake in O2 Renewables on a fully diluted basis. This strategic acquisition will not only bolster GPL’s commitment to environmental responsibility but also enable the company to comply with Indian electricity laws regarding captive power usage. Following the acquisition, O2 Renewables will become an associate of GPL.
• Power Purchase Agreement: This agreement ensures GPL’s access to clean energy generated by O2 Renewables. By procuring renewable power, GPL can significantly reduce its carbon footprint and contribute to a cleaner environment.

Investing in a Sustainable Future

The total consideration for the 26% stake acquisition is ₹1,75,00,000, payable in cash. The subscription to equity shares and compulsorily convertible debentures is expected to be finalised within approximately three months from the signing date. This swift execution timeline underscores GPL’s dedication to achieving its sustainability goals.

Overview of O2 Renewable Energy

Established in February 2024, O2 Renewables is a company dedicated to harnessing the power of renewable energy sources like solar energy. Their core operations encompass the generation, production, and distribution of clean electricity. The company operates in grid-connected and off-grid modes, catering to a wider range of energy needs. This comprehensive approach aligns perfectly with GPL’s commitment to a sustainable future.

Looking Ahead

Glenmark Pharmaceuticals‘ strategic investment in O2 Renewable Energy signifies a significant step forward on its journey towards carbon neutrality by 2030. This move might position GPL as a leader in sustainable business practices within the Indian pharmaceutical industry.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.